DiaMedica Therapeutics Inc. (NASDAQ: DMAC) reported Q2 EPS of ($0.13), $0.03 better than the analyst estimate of ($0.16).

For earnings history and earnings-related data on DiaMedica Therapeutics Inc. (DMAC) click here.